» Articles » PMID: 18697945

Metastatic Osteosarcoma Induced by Inactivation of Rb and P53 in the Osteoblast Lineage

Abstract

Mutation of the RB-1 and p53 tumor suppressors is associated with the development of human osteosarcoma. With the goal of generating a mouse model of this disease, we used conditional and transgenic mouse strains to inactivate Rb and/or p53 specifically in osteoblast precursors. The resulting Rb;p53 double mutant (DKO) animals are viable but develop early onset osteosarcomas with complete penetrance. These tumors display many of the characteristics of human osteosarcomas, including being highly metastatic. We established cell lines from the DKO osteosarcomas to further investigate their properties. These immortalized cell lines are highly proliferative and they retain their tumorigenic potential, as judged by their ability to form metastatic tumors in immunocompromised mice. Moreover, they can be induced to differentiate and, depending on the inductive signal, will adopt either the osteogenic or adipogenic fate. Consistent with this multipotency, a significant portion of these tumor cells express Sca-1, a marker that is typically associated with stem cells/uncommitted progenitors. By assaying sorted cells in transplant assays, we demonstrate that the tumorigenicity of the osteosarcoma cell lines correlates with the presence of the Sca-1 marker. Finally, we show that loss of Rb and p53 in Sca-1-positive mesenchymal stem/progenitor cells is sufficient to yield transformed cells that can initiate osteosarcoma formation in vivo.

Citing Articles

Primary Bone Tumors and Breast Cancer-Induced Bone Metastases: In Vivo Animal Models and New Alternative Approaches.

Ucci A, Giacchi L, Rucci N Biomedicines. 2024; 12(11).

PMID: 39595017 PMC: 11591690. DOI: 10.3390/biomedicines12112451.


Loss Enhances Disease Progression in a Murine Model of Osteosarcoma.

Fatema K, Wang Y, Pavek A, Larson Z, Nartker C, Plyler S Cancers (Basel). 2024; 16(15).

PMID: 39123453 PMC: 11311538. DOI: 10.3390/cancers16152725.


Myc upregulates Ggct, γ-glutamylcyclotransferase to promote development of p53-deficient osteosarcoma.

Ueno T, Otani S, Date Y, Katsuma Y, Nagayoshi Y, Ito T Cancer Sci. 2024; 115(9):2961-2971.

PMID: 38924236 PMC: 11462974. DOI: 10.1111/cas.16255.


Collagen type X expression and chondrocyte hypertrophic differentiation during OA and OS development.

Han T, Zhu T, Lu Y, Wang Q, Bian H, Chen J Am J Cancer Res. 2024; 14(4):1784-1801.

PMID: 38726262 PMC: 11076255. DOI: 10.62347/JWGW7377.


PRRX1-TOP2A interaction is a malignancy-promoting factor in human malignant peripheral nerve sheath tumours.

Takihira S, Yamada D, Osone T, Takao T, Sakaguchi M, Hakozaki M Br J Cancer. 2024; 130(9):1493-1504.

PMID: 38448751 PMC: 11058259. DOI: 10.1038/s41416-024-02632-8.


References
1.
Wang X, Kua H, Hu Y, Guo K, Zeng Q, Wu Q . p53 functions as a negative regulator of osteoblastogenesis, osteoblast-dependent osteoclastogenesis, and bone remodeling. J Cell Biol. 2005; 172(1):115-25. PMC: 2063539. DOI: 10.1083/jcb.200507106. View

2.
Gurney J, Severson R, Davis S, Robison L . Incidence of cancer in children in the United States. Sex-, race-, and 1-year age-specific rates by histologic type. Cancer. 1995; 75(8):2186-95. DOI: 10.1002/1097-0142(19950415)75:8<2186::aid-cncr2820750825>3.0.co;2-f. View

3.
Tirode F, Laud-Duval K, Prieur A, Delorme B, Charbord P, Delattre O . Mesenchymal stem cell features of Ewing tumors. Cancer Cell. 2007; 11(5):421-9. DOI: 10.1016/j.ccr.2007.02.027. View

4.
Rodda S, McMahon A . Distinct roles for Hedgehog and canonical Wnt signaling in specification, differentiation and maintenance of osteoblast progenitors. Development. 2006; 133(16):3231-44. DOI: 10.1242/dev.02480. View

5.
Thomas D, Carty S, Piscopo D, Lee J, Wang W, Forrester W . The retinoblastoma protein acts as a transcriptional coactivator required for osteogenic differentiation. Mol Cell. 2001; 8(2):303-16. DOI: 10.1016/s1097-2765(01)00327-6. View